These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35101112)

  • 1. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018.
    Conway KP; Khoury D; Hilscher R; Aldridge AP; Parker SJ; Zarkin GA
    Addict Sci Clin Pract; 2022 Jan; 17(1):5. PubMed ID: 35101112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.
    Andrilla CHA; Patterson DG
    J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver.
    McKnight ER; Dong Q; Brook DL; Hepler SA; Kline DM; Bonny AE
    Cureus; 2023 Mar; 15(3):e36903. PubMed ID: 37139287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between buprenorphine provider availability and opioid deaths among US counties.
    Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
    J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine.
    Nguemeni Tiako MJ; Culhane J; South E; Srinivas SK; Meisel ZF
    JAMA Netw Open; 2020 Dec; 3(12):e2029043. PubMed ID: 33306115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Opioid Use Disorder Treatment in Priority Areas: The Role of Certified Nurse-Midwives.
    Kane C; Topmiller M
    J Midwifery Womens Health; 2022 May; 67(3):314-320. PubMed ID: 35506768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadband access and telemedicine adoption for opioid use disorder treatment in the United States.
    Ali MM; Ghertner R
    J Rural Health; 2023 Jan; 39(1):233-239. PubMed ID: 35838414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States.
    Kiang MV; Barnett ML; Wakeman SE; Humphreys K; Tsai AC
    Drug Alcohol Depend; 2021 Nov; 228():109081. PubMed ID: 34600256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes.
    Hirchak KA; Amiri S; Kordas G; Oluwoye O; Lyons AJ; Bajet K; Hahn JA; McDonell MG; Campbell ANC; Venner K
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):41. PubMed ID: 35614487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
    Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
    Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.
    Stringfellow EJ; Lim TY; Dong H; Zhang Z; Jalali MS
    Addiction; 2023 Nov; 118(11):2215-2219. PubMed ID: 37434347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2019 evaluation of opioid use disorder treatment resources in rural Utah counties.
    Ragsdale RJ; Nickman NA; Slager S; Fox ER
    J Am Pharm Assoc (2003); 2021; 61(5):513-521. PubMed ID: 33933362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    JAMA Netw Open; 2019 Dec; 2(12):e1916520. PubMed ID: 31790568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.